DESIGNATED FEDERAL OFFICER (Non-Voting)

Stephanie L. Begansky, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Brendan M. Everett, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director, General Cardiology Inpatient Service, Brigham and Women’s Hospital
Boston, Massachusetts

James D. Neaton, PhD
Professor of Biostatistics
Division of Biostatistics
Coordinating Centers for Biometric Research
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Diana Hallare, MPH
(Consumer Representative)
Visalia, California

Robert J. Smith, MD
(Chairperson)
Professor of Medicine (Endocrinology)
Alpert Medical School of Brown University
Ocean State Research Institute
Providence Veterans Administration (VA) Medical Center
Providence, Rhode Island

Susan R. Heckbert, MD, PhD
Professor
Department of Epidemiology
University of Washington
Seattle, Washington

Peter W. F. Wilson, MD
Director, Epidemiology and Genomic Medicine
Atlanta Veterans Administration Medical Center
Professor of Medicine and Public Health
Emory University
Emory Clinical Cardiovascular Research Institute
Atlanta, Georgia

William R. Hiatt, MD, FACP, FAHA
Professor of Medicine
Division of Cardiology
University of Colorado School of Medicine
President, Colorado Prevention Center (CPC)
Clinical Research
Aurora, Colorado
ENDOCRINOLOGIC AND METABOLIC DRUG PRODUCTS ADVISORY COMMITTEE
MEMBER (Non-Voting)

Mads F. Rasmussen, MD, PhD
(Industry Representative)
Project Vice President
GLP-1 and Obesity
Global Development
Novo Nordisk A/S
Denmark

TEMPORARY MEMBERS (Voting)

Diane M. Biskobing, MD
Professor of Medicine
Program Director, Endocrinology and Metabolism Fellowship
Virginia Commonwealth School of Medicine
Richmond, Virginia

Stuart S. Howards, MD
Professor of Urology
University of Virginia
Charlottesville, Virginia
Wake Forest Medical School
Winston Salem, North Carolina

Daniel Budnitz, MD, MPH
CAPT, US Public Health Service
Director, Medication Safety Program
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

John Lavelle, MD
Associate Professor of Urology
Stanford University
Staff Physician
Veterans Affairs Hospital
Palo Alto, California

Toby C. Chai, MD
Professor of Urology
Vice Chair of Research
Department of Urology
Yale School of Medicine
Co-Director of FPMRS Program
Yale-New Haven Hospital
New Haven, Connecticut

Kevin D. McBryde, MD
Program Director
Office of Minority Health and Research Coordination
National Institute of Diabetes, Digestive, and Kidney Diseases, NIH
Bethesda, Maryland

Jonathan Emens, MD
Associate Professor, Department of Psychiatry
Assistant Professor, Department of Medicine
Oregon Health & Science University
Sleep Lab Director and Staff Physician
VA Portland Health Care System
Portland, Oregon

Shirley Miller
(Patient Representative)
Charlotte, North Carolina
### TEMPORARY MEMBERS (Voting) (cont.)

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martha Nason, PhD</td>
<td>Mathematical Statistician</td>
<td>Biostatistics Research Branch, Division of Clinical Research</td>
<td>Bethesda, Maryland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)</td>
<td></td>
</tr>
<tr>
<td>Christian Pavlovich, MD</td>
<td>Associate Professor, Urology</td>
<td>James Buchanan Brady Urological Institute</td>
<td>Baltimore, Maryland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Johns Hopkins University School of Medicine</td>
<td></td>
</tr>
</tbody>
</table>

### FDA PARTICIPANTS (Non-Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Marc Guettier, MD</td>
<td>Director, Division of Metabolism and Endocrinology Products (DMEP)</td>
<td>Office of Drug Evaluation (ODE) II, Office of New Drugs (OND), CDER, FDA</td>
<td></td>
</tr>
<tr>
<td>Mark Hirsch, MD</td>
<td>Medical Team Leader in Urology</td>
<td>Division of Bone, Reproductive and Urologic Products (DBRUP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ODE III, OND, CDER, FDA</td>
<td></td>
</tr>
<tr>
<td>William Lubas, MD, PhD</td>
<td>Medical Officer</td>
<td>DMEP, ODE II, OND, CDER, FDA</td>
<td></td>
</tr>
<tr>
<td>Roger Wiederhorn, MD</td>
<td>Medical Officer</td>
<td>DBRUP, ODE III, OND, CDER, FDA</td>
<td></td>
</tr>
</tbody>
</table>